Fructose transporter GLUT5 expression in clear renal cell carcinoma.

Oncol Rep

INIBIC, CHU A Coruña, Oncology Group, Department of Pathology, Xubias de Abaixo s/n, 15006 A Coruña, Spain.

Published: February 2011

Renal cell carcinomas (RCC) can be subclassified for general purposes into clear cell, papillary cell, chromophobe cell carcinomas and oncocytomas. Other tumours such as collecting duct, medullary, mucinous tubular and spindle cell and associated with Xp 11.2 translocations/TFE 3 gene fusion, are much less common. There is also a residual group of unclassified cases. Previous studies have shown that RCC has high glycolytic rates, and expresses GLUT transporters, but no distinction has been made among the different subtypes of renal cell tumours and their grades of malignancy. In clear renal cell carcinoma (cRCC) glycogen levels increase, glycolysis is activated and gluconeogenesis is reduced. The clear cell subtype of RCC is characterized histologically by a distinctive pale, glassy cytoplasm and this appearance of cRCC is due to abnormalities in carbohydrate and lipid metabolism, and this abnormality results in glycogen and sterol storage. Several isoforms of glucose carriers (GLUTs) have been identified. We show here in a panel of 80 cRCC samples a significant correlation between isoform 5 (GLUT5) and many pathological parameters such as grade of differentiation, pelvis invasion and breaking capsule. GLUT5 expression also appears to associate more strongly with the clear cell RCC subtype. These data suggest a role for the GLUT5 isoform in fructose uptake that takes place in cRCC cells and which subsequently leads to the malignant RCC progression.

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2010.1096DOI Listing

Publication Analysis

Top Keywords

renal cell
16
clear cell
12
cell
10
glut5 expression
8
clear renal
8
cell carcinoma
8
cell carcinomas
8
clear
5
rcc
5
fructose transporter
4

Similar Publications

ERMP1 as a newly identified ER stress gatekeeper in chronic kidney disease.

Am J Physiol Renal Physiol

January 2025

Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

ERMP1 is involved in the Unfolded Protein Response (UPR) pathway in response to endoplasmic reticulum (ER) stress. Given the pivotal role of ER stress in the pathogenesis of acute and chronic kidney diseases, we hypothesized that ERMP1 could be instrumental in the development of renal injury. analysis of RNA sequencing datasets from renal biopsies were exploited to assess the expression of ERMP1 in the kidney under normal or pathological conditions.

View Article and Find Full Text PDF

A novel spraying nanoprobe for renal cell carcinoma in humans.

Life Med

February 2023

Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

View Article and Find Full Text PDF

Pan-Cancer Analysis of the Prognostic and Immunotherapeutic Value of PDGFB.

Immunotargets Ther

January 2025

Institute of Integration of Traditional Chinese and Western Medicine, The Hospital Affiliated to Jiangnan University, Wuxi, People's Republic of China.

Introduction: Cancer is a widespread epidemic that affects millions of individuals across the world. Identifying novel cancer targets is crucial to developing more effective cancer treatments. Platelet-derived growth factor-B (PDGFB) plays a critical role in various tumor processes, including angiogenesis and lymphatic metastasis.

View Article and Find Full Text PDF

The advent of immune checkpoint inhibitors (ICIs) has transformed the management of advanced and high-risk renal cell carcinoma (RCC). In the adjuvant setting, ICIs, such as pembrolizumab, aim to reduce the risk of recurrence following potentially curative nephrectomy. However, this therapeutic approach introduces unique challenges, particularly related to immune-related adverse events (irAEs).

View Article and Find Full Text PDF

Inferior vena cava (IVC) invasion by tumor thrombus poses a significant surgical challenge, often requiring vascular reconstruction. Standard methods, including prosthetic and autologous vein grafts, have limitations such as infection risks, anticoagulation demands, and increased costs. We present the case of a 66-year-old male with a right renal tumor (T3bN0M0, Neves Zincke II) and gross hematuria, who underwent radical nephrectomy with open thrombectomy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!